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History
• Spiegeman and his colleagues publish their work with nucleic acid in 
1960. 
• The result was the invention of PCR in 1986 by Molis.
• In 1990  SELEX  (Selective expansion of ligands by exponential 
enrichment) were invented.
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 Aptamers ( By Ellington) are oligonucleotides
 (DNA or RNA) that can bind with high affinity 
 specificity to a wide range of target molecules 
such as drugs, proteins or other organic or in 
organic molecules 
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Aptamers, derived from the Latin 
aptus,meaning ‘‘to fit”
• Each RNA molecules have specific sequences of nucleic acids.
• These molecules bind to different positions 
• Establish hydrogen bonds and van der Waals molecules 
• These RNA are called  Aptamer and the  binding site are
named  Aptatop. 
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Aptamers VS Antibodies
Aptamers Antibodies
Affinity Low nM to pM Low nM to pM
Specificity High High
Production In Vitro Chemical 
Process
In Vivo Biological 
Systems
Target Range* Wide: Ions, Cell, Toxins Narrow: Immunogenics
Batch to Batch 
Variation
Little or No Significant
Chemical Modification* Easy Limited
Thermal Denaturation Reversible Irreversible
7
Aptamers: Denser immobilization on the surface
Aptamers: Nuclease sensitive
Creation of Aptamers
• Aptamers are generated by an iterative selection process, called 
systematic evolution of ligands by exponential enrichment (SELEX). 
• SELEX technology have extended aptamer selection from 
comparatively simple mixtures of purified proteins to whole living 
cells.
• SELEX isolate Aptamers that bind to specific target cells.
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SELEX
 SELEX is a multi-step process in which strongly bind
 ligands are preferably selected by rounds of affinity assays and PCR
amplification
 The SELEX method has permitted the identification of unique RNA/DNA 
molecules which bind to the target with very high affinity and specificity
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Systematic Evolution Of Ligands By EXponential Enrichment
[2] 10
[3]
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circular dichroism spectroscopy
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• A sensor is a device that transforms environmental information, ranging from
the concentration of a specific sample component to total 
• composition analysis, into an analytically useful signal.
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Transducer RecorderReceptor
Antibody
Enzyme
Microorganism
Aptamer
Recognition Part
Transducer
Electrochemical
Thermal
Optical
Mass Changes
Bio sensors
Essential Factors for 
Biosensors Operation 
• Sensitivity to presence of target
• The fabricated biosensor should show sensitivity to the presence of its 
own target. 
• Linearity  of response
• The response of biosensor should be proportional to the concentration of 
its target.
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• Selectivity
• Chemicals interference must be minimized for obtaining the correct 
result.
• Reproducibility
• The response of the biosensor to the presence of target should be 
reproducible.
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Detection of Aptamer
• Using affinity surfaces
• Using affinity tags
• Using column matrices or ligands
• Nitrocellulose membrane filtration
• Cross-linking
• Antibody-based
• Surface plasmon resonance
• Capillary electrophoresis
• Flow cytometry
• Automated selection
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Using affinity surfaces
• Affinity surfaces: allow proteins and small molecules to bind with 
them & have affinities with RNA or DNA.
• Magnetic beads, affinity titer plates
• RNA Aptamer against Panama  influenza virus subtype A
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STEP2
Negative
selection
•Incubating the pool 
RNA with the BSA-
coated beads in binding 
buffer for 10 min.
Step 3
Counter selection
•The unbound RNA was 
collected with the help of 
magnet and applied onto 
beads coated with the same 
subtype A/Aichi virus as the 
counter-selection to remove 
molecules specific to A/Aichi.
•Incubating for 10 min.
STEP4
selection
•The unbound molecules were again 
collected and incubated with beads 
coated with the target A/Panama virus
•After this incubation, the beads were 
washed three times with 300 μl of 
binding buffer. 
•Bound RNAs were recovered with a 
hot 7M urea solution.
•Bound molecules were precipitated 
by ethanol.
STEP5
Amplification
•Reverse transcription
•PCR
•In vitro transcription
Step 1
Preparation
•Coating the whole virus onto 
beads
•BSA Blocking
•Washing the coated beads.
•Denaturing the pool RNA(90 °C 
for 2 min and allowed to cool at 
room temperature for 10 min)
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Using capillary electrophoresis
• The nucleic acid sequences that bind the target undergo a mobility shift.
• no need to wash the active sequences off a column as in conventional 
SELEX, eliminating any kinetic bias.
• Higher speed, better resolution capacity, minimal sample dilution, fewer 
cycles.
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Fluorescent signals
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Application 
• Therapeutic Target
• Analytic Detection
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APTAMER TO THERAPEUTIC TARGET 
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APTAMER TO THERAPEUTIC TARGET 
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Aptamer and Epidermal growth factor receptor 
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• Epidermal growth factor receptor (EGFR/HER1/c-ErbB1), is 
overexpressed in many solid cancers.
• TuTu22 aptamer was able to recognize cancer cells expressing EGFR 
but did not bind to the EGFR-negative cells. 
• This DNA aptamers will facilitate the development of novel targeted 
tumor cell detection, cancer cell imaging and cancer therapy. 
analytical applications
Affinity Chromatography
Capillary Electrophoresis
 In vitro and in vivo diagnostic tools
Targeting intracellular target molecules
Drug Discovery
Therapy
Protein Purification
Diagnostics
ELISA
Western Blotting
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 The first aptamer to a nucleotide was isolated in 1993 by Sassanfar and 
Szostak
 In 2004 RNA selection   aptamers that recognized the triphosphate of 
ATP were selected in the laboratory of Jack W. Szostak (Sazani et al., 2004)
 Interact with the part of the target molecule that faced the matrix, but 
did not strongly interact with the part that had greatest accessibility.  
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Analytic Detection:Aptamers to Nucleic Acid
Conclusion  
• Aptamer technology has made significant strides.
• Aptamers can be applied to many fields of molecular medicine
• The identification of aptamer molecular targets constitutes a novel 
method of biomarker discovery
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• Cell-specific aptamers can be readily adapted for drug delivery and 
targeted therapy
• Cell-SELEX represents an integrated technology that will revolutionize 
the way we diagnose, treat and prevent disease
• represents an integrated technology that will revolutionize the way 
we diagnose, treat and revent disease.
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Research Perspectives
Aptamers are the very astonish way to diagnose  and  diagnosis 
disease 
It seems using Aptamer will help us one step closer to understanding 
all sort of sickness especially  in cancer world
Limitation and weakness point of this knowledge is still under 
observation
Also we still need more aptamer in order to diagnose more and 
specific illness.
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